» Articles » PMID: 12848798

Knowledge Deficits Related to the QT Interval Could Affect Patient Safety

Overview
Date 2003 Jul 10
PMID 12848798
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recently, some QT-prolonging, noncardiac medications were withdrawn from the U.S. drug market because of continued inappropriate use by health care practitioners despite warnings and label changes from both the drug manufacturers and the U.S. Food and Drug Administration. This led us to assess the health care practitioners' knowledge of the QT interval and medications that may prolong it.

Methods: We surveyed health care practitioners, primarily specialists in cardiology, to identify knowledge deficits related to the QT interval.

Results: From a total of 334 survey respondents, 157 (47%) were physicians; 271 (81%) stated that cardiology was their area of specialization. Most of the respondents (86%) said that they would check an ECG before and after starting QT-prolonging medications, but less than half (42%) of all respondents and only 60% of physician respondents were able to accurately measure a sample QT interval on the survey. Less than two-thirds (63%) of respondents were able to accurately identify possible QT-prolonging medications, while only about half (51%) could accurately identify medication combinations that might prolong the QT interval.

Conclusions: We identified significant knowledge deficits regarding the QT interval and QT-prolonging medications. Additional research is needed to determine the extent to which these knowledge deficits may negatively affect patient safety. We must also develop effective strategies to eliminate these deficits.

Citing Articles

[Arrhythmias education-current considerations with a focus on ECG teaching].

Raupach T Herzschrittmacherther Elektrophysiol. 2024; 36(1):91-95.

PMID: 39621055 DOI: 10.1007/s00399-024-01057-3.


Prolonged QT Interval in SARS-CoV-2 Infection: Prevalence and Prognosis.

Farre N, Mojon D, Llagostera M, Belarte-Tornero L, Calvo-Fernandez A, Valles E J Clin Med. 2020; 9(9).

PMID: 32839385 PMC: 7563186. DOI: 10.3390/jcm9092712.


Use of QT Prolonging Medications by Hemodialysis Patients and Individuals Without End-Stage Kidney Disease.

Assimon M, Wang L, Pun P, Winkelmayer W, Flythe J J Am Heart Assoc. 2020; 9(13):e015969.

PMID: 32578475 PMC: 7670513. DOI: 10.1161/JAHA.120.015969.


Identification of Patients At-Risk of QT Interval Prolongation during Medication Reviews: A Missed Opportunity?.

Buss V, Lee K, Naunton M, Peterson G, Kosari S J Clin Med. 2018; 7(12).

PMID: 30544669 PMC: 6306817. DOI: 10.3390/jcm7120533.


Summative assessments are more powerful drivers of student learning than resource intensive teaching formats.

Raupach T, Brown J, Anders S, Hasenfuss G, Harendza S BMC Med. 2013; 11:61.

PMID: 23497243 PMC: 3635879. DOI: 10.1186/1741-7015-11-61.


References
1.
Schouten E, Dekker J, Meppelink P, Kok F, Vandenbroucke J, Pool J . QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation. 1991; 84(4):1516-23. DOI: 10.1161/01.cir.84.4.1516. View

2.
Frothingham R . Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy. 2002; 21(12):1468-72. DOI: 10.1592/phco.21.20.1468.34482. View

3.
Malik M . Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol. 2001; 12(4):411-20. DOI: 10.1046/j.1540-8167.2001.00411.x. View

4.
Friedman M, Woodcock J, Lumpkin M, Shuren J, Hass A, Thompson L . The safety of newly approved medicines: do recent market removals mean there is a problem?. JAMA. 1999; 281(18):1728-34. DOI: 10.1001/jama.281.18.1728. View

5.
Reilly J, Ayis S, Ferrier I, Jones S, Thomas S . QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000; 355(9209):1048-52. DOI: 10.1016/s0140-6736(00)02035-3. View